Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05246228

Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy — HR-cSCC  

Squamous Cell Carcinoma of the Skin Clinical Trial

Official title:
Immune System Modulation and Outcome in High-risk Cutaneous Squamous Cell Carcinoma Treated With Surgery and Radiotherapy: a Prospective Study

Clinical Trial Summary

Treatment with adjuvant radiotherapy modulates immune system in many diseases as witnessed by dynamic changes of humoral and cellular immunity. Moreover, the persistent lymphopenia after radiation therapy is a negative prognostic factor. This study is aimed to explore the changes in immune-cell populations during radiotherapy given as adjuvant treatment for high-risk cutaneous squamous cell carcinomas and to correlate them with patient's outcome.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05246228
Study type Observational
Source Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Contact Aldo Roccaro, MD
Phone +39 0303996851
Email coordinamento.ricerca@asst-spedalicivili.it
Status Not yet recruiting
Phase
Start date March 1, 2022
Completion date December 30, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Active, not recruiting NCT06327971 - Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology
Not yet recruiting NCT03621462 - Elucid Labs AIDA™ - Labelled Image Acquisition Protocol N/A
Not yet recruiting NCT04480645 - CivaDerm(TM) Surface Therapy Pilot Study Early Phase 1
Recruiting NCT03370861 - How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Recruiting NCT06014086 - Intratumoral PH-762 for Cutaneous Carcinoma Phase 1
Completed NCT02347813 - Preventing Squamous Cell Skin Cancer Phase 2
Terminated NCT01984892 - Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) Phase 2
Completed NCT00563290 - Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT04204837 - Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin Phase 2
Active, not recruiting NCT03894618 - SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Phase 1
Terminated NCT01823679 - Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Phase 2
Completed NCT00126555 - Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Phase 2
Completed NCT00089180 - T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant Phase 2
Recruiting NCT05886140 - Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin N/A
Completed NCT02324608 - Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer N/A
Recruiting NCT02717936 - Investigation of Desmoplastic Squamous Cell Carcinoma N/A
Recruiting NCT05482880 - Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
Withdrawn NCT01465815 - Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) Phase 1/Phase 2
Recruiting NCT05490485 - Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma Phase 2